- Q1 revenues up 38% to new record of € 3.3 million thanks to broadband virus blocker Carragelose
- Carragelose: Preparations for market entry in the USA and extension of use to allergic indications in full swing
- Marinosolv: Full focus on commercialization of product candidates Tacrosolv and Budesolv
- Financial outlook for full year 2023 confirmed
The full press release is available as download here: